ClinicalTrials.gg
TerminatedNCT03036878Updated Jan 18, 2020

ReNu™ Marrow Stimulation Augmentation

An interventional study of ReNu in Osteochondral Defect, sponsored by NuTech Medical, Inc. Terminated at 2 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by NuTech Medical, Inc (part of Organogenesis) · Not applicable, Interventional, and Treatment

Why this study was terminated
Closed for lack of enrollment
Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To evaluate the use of ReNu™ allograft for the augmentation of marrow stimulation for osteochondral lesions

Read the detailed description

This is a prospective, non-randomized, longitudinal study of up to 8 evaluable participants recruited from two separate practices. Male and non-pregnant female patients between the ages of 18 and 55 years of age will be screened for study recruitment. Female patients must be actively practicing a contraception method, abstinence, be surgically sterilized, or be postmenopausal. Participants will receive ReNu™ as an adjunct to their standard of care marrow stimulation for the treatment of osteochondral defects.

At each follow-up visit, concomitant medications and adverse events shall be collected from each subject, and each subject shall complete the following questionnaires:

IKDC Health Assessment (Includes Short Form-36) Tegner KOOS Knee Survey VAS Pain Scale SANE score

The subjects will be assessed at Baseline using these scales an again at all subsequent study follow-up visits.

02

Conditions studied

  • Osteochondral Defect

Keywords

  • Osteochondral
  • Marrow Stimulation
  • ReNu
03

In context

Lead sponsor

NuTech Medical, Inc is the lead sponsor of 9 studies on the registry; none are open to participants now.

First submitted before NuTech Medical, Inc became part of Organogenesis.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary signature of the IRB approved
  2. Male or female participants between the ages of 18-55
  3. If female:

    1. Actively practicing a method, or
    2. Practicing abstinence, or
    3. Surgically sterilized, or
  4. Pretreatment arthroscopic confirmation indicating one or two contained lesion(s) and equal to an ICRS Grade 3a, 3b, 3c, 3d of the femoral condyle, patella, or trochlear groove and OCD lesions (Grade 4a) with healed bone base, which is non-sclerotic and no loss of bone greater then 6mm measured from the surrounding subchondral plate. Original pretreatment arthroscopic confirmation indicates that one or two lesion(s) are equal to an ICRS Grade 3a, 3b, 3c, 3d contained lesion(s) that is equivalent to an Outerbridge Grade III or IV (greater than 50% loss of articular cartilage). OF NOTE: Patients with need for concomitant procedures such as Anteromedialization of Tibial Tubercle (AMZ) and lateral lengthening are allowable
  5. Has peripheral cartilage debridement to healthy cartilage that results in a lesion (s) with an area of > or = 1cm \^2 and \< or = 4 cm\^2.
  6. PCL, LCL and MCL in the affected knee are stable and the ACL is stable or can be stabilized as a concomitant procedure.
  7. Ipsilateral knee compartment has intact menisci (or requires partial meniscectomy resulting in stable menisci). Minimum remnant width of 5mm.
  8. The contralateral knee is asymptomatic, stable, and fully functional.
  9. Must be physically and mentally willing and able to comply with post-operative rehabilitation and routinely scheduled clinical and radiographic visits through 24 months.
  10. Alignment: Mechanical axis must be no more than 5 degrees from neutral.
  11. Must be 3 months post previous surgery.

Exclusion criteria

Exclusion Criteria:

  1. Clinical and/or radiographic disease diagnosis of the indexed affected joint that Includes:

    1. Osteoarthritis or avascular necrosis,
    2. Rheumatoid arthritis, or history of septic or reactive arthritis,
    3. Gout or history of gout or pseudogout in the affected knee,
    4. Osteochondritis dissecans of the knee with significant bone loss (greater than 6mm deep from the subchondral plate)
    5. Associated damage to the underlying subchondral bone requiring a bone graft
  2. History of secondary arthropathies (i.e. sickle cell disease, hemochromatosis, or disease).
  3. Uncontrolled diabetes.
  4. Displays a high surgical risk due to unstable cardiac and/or pulmonary disease.
  5. Has or other immunodeficient state including subjects on therapies, or has significant illness ( of any type) that decreases the probability of survival to the 2 year endpoint.
  6. Is at substantial risk for the need of organ transplantation, such as renal insufficiency.
  7. Is pregnant or breast-feeding.
  8. > 35.
  9. Has bipolar articular cartilage involvement or kissing lesions of the ipsilateral compartment, described as tibial or patellar lesions in the same compartment with greater than ICRS Grade 2 chondrosis.
  10. Is participating concurrently in another clinical trial, or has participated in a clinical trial within 30 days of surgery.
  11. Is receiving prescription pain medication other than NSAIDs or acetaminophen for conditions unrelated to the index knee condition, chronic use of anticoagulants, or taking .
  12. Has a neuromuscular, neurosensory, or musculoskeletal deficiency that limits the ability to perform objective functional assessment of either knee.
  13. Active joint infection.
  14. Prior total meniscectomy of either knee.
  15. Radiographically has >5 degrees of malalignment as measured from the hip, knee and ankle mechanical axis.
  16. Has subchondral bone loss of greater than 6mm
  17. Has received within the past three months intra-articular rich plasma, hyaluronic acid therapy, steroid, amniotic-derived or stem cell injections in the index knee.
  18. Prior realignment surgery in the affected knee within the past 6 months.
  19. Failed microfracture/marrow stimulation treatment performed less than 12-months before baseline.
  20. Is receiving workman's compensation or currently involved in litigation relating to the index knee.
  21. Has history of alcoholism, medication, or intravenous drug abuse, psychosis, is a prisoner, has a personality disorder (s), poor motivation, emotional or intellectual issues that would likely make the subject unreliable for the study, or any combination of variables in the investigator's judgment that should exclude a potential subject.
  22. Any conditions or implants that might affect having MRIs: had or have an aneurysm clip implanted, intraocular foreign bodies (commonly seen in welders), subcutaneous metal shards (found in sheet metal workers), or some shrapnel; additionally, no cardiac pacemaker, defibrillator, implanted neurostimulater (TENS implants) some prosthetic heart valve (especially mitral valve), cochlear implant or other hearing aide. Subjects should be excluded if they have a tendency of claustrophobia or have tattoos that may contain iron-based dyes.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    ReNu Injection

    Injection of ReNu allograft into the joint capsule.

    Other: ReNu

Interventions

  • OtherReNu

    ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.

06

What researchers measure

Primary outcomes

  1. Change in KOOS score from baseline

    Time frame: 1 Year

  2. Change in Tegner score from baseline

    Time frame: 1 Year

Secondary outcomes

  1. Change in VAS score from baseline

    Time frame: 6, 12 & 24 months

  2. Change in Tegner score from baseline

    Time frame: 6 & 24 months

  3. Change in SANE score from baseline

    Time frame: 6, 12 & 24 months

  4. Change in KOOS score from baseline

    Time frame: 6 & 24 months

07

Study locations

2 sites
  • Orthoindy
    Indianapolis, Indiana 46143, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Dec 2019, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2017
First posted
Jan 30, 2017
StartActual
Feb 7, 2017
Primary completionActual
Dec 6, 2019
CompletionActual
Dec 6, 2019
Last update
Jan 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03036878
Collaborators
Organogenesis
Responsible party
Sponsor
First posted
Jan 30, 2017
Start date
Feb 7, 2017
Primary completion
Dec 6, 2019
Completion
Dec 6, 2019
Last update
Jan 18, 2020

Study contacts

Jack Farr, MD
principal investigator · OrthoIndy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion